<--- Back to Details
First PageDocument Content
Immunosuppressants / Mineral trioxide aggregate / Bevacizumab / Eczema / Paclitaxel / Atopic dermatitis / Cognitive behavioral therapy / Prostate cancer / Capecitabine / Medicine / Chemistry / Organic chemistry
Date: 2015-04-13 11:02:21
Immunosuppressants
Mineral trioxide aggregate
Bevacizumab
Eczema
Paclitaxel
Atopic dermatitis
Cognitive behavioral therapy
Prostate cancer
Capecitabine
Medicine
Chemistry
Organic chemistry

Appraisal Number Year of Publication Process Technology Condition Categorisation Comment TA001 2000 MTA Prophylactic removal Wisdom teeth Recommended Recommendation in line with clinical practice. Moved to static list (r

Add to Reading List

Source URL: www.nice.org.uk

Download Document from Source Website

File Size: 1.022,00 KB

Share Document on Facebook

Similar Documents

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

DocID: 1rrNB - View Document

Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis rev. 2

Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis rev. 2

DocID: 1rmwo - View Document

EAP Reimbursement Criteria for Frequently Requested Drugs

EAP Reimbursement Criteria for Frequently Requested Drugs

DocID: 1rhhE - View Document

UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol

UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol

DocID: 1rakB - View Document

TABLE OF CONTENTS  INTRODUCTION 2

TABLE OF CONTENTS INTRODUCTION 2

DocID: 1qY7G - View Document